Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of Cavacini, Lisa
keywords Immunotherapy, Passive

The major focus of my laboratory research is in the area of immunoregulation of infectious disease, cancer and autoimmune disease. Human monoclonal antibodies are characterized to study the humoral immune response in these disorders. . In addition, the laboratory is interested in developing active and passive forms of immunotherapy for the treatment of these disease areas. Not only do we generate new human monoclonal antibodies for our studies, but also for a large number of laboratories throughout the world for research on infectious diseases, cancer and autoimmune disease. We collaborate with Drs. Greiner, Brehm and Luban here at UMMS and Dr. Leonard Schultz at Jackson Laboratories on humanized mouse models for the generation of human monoclonal antibodies and as models for passive immunotherapy for bacterial or viral infections. The laboratory has also been involved in pharmacokinetic and pharmacodynamic studies of IgG and IgA human monoclonal antibodies, in several bacterial and viral infections. To further develop Dr. Cavacini’s background in mucosal immunology, included in this work is structural modeling of antibody/antigen interactions to improve the design of immunotherapeutic antibodies and development of a platform for production of dimeric and secretory IgA. These leading activities in IgA immunotherapy are currently being translated into clinical development of mucosal IgA molecules for prevention or treatment of two diverse bacterial infections. In addition to Dr. Cavacini’s current work on immunoprophylaxis for mucosal bacterial infections (e.g. Enterotoxigenic Escherichia coli,, Bordetella pertussis, Klebsiella pneumonia), she is also inventor of two human monoclonal antibodies against Staphylococcus aureus and Pseudomonas aeruginosa. Dr. Cavacini also contributes to programs for Lyme Disease and other emerging pathogens. Most recently, this has been to generate reagents and establish assays for screening novel drug candidates for immunoprophylaxis or treatment of COVID-19. Our initial screen of MassBiologics’ existing panel of SARS-CoVspecific antibodies resulted in Mabs with ELISA binding activity to the receptor binding domain of the SARS-CoV-2 Spike protein.  We have moved on to nanobody discovery for broadly neutralizing antibodies against all variants of concern and interest.  The expertise at MassBiologics, particularly in the areas of Discovery and Process Development, has allowed rapid production of SARS CoV-2 proteins (including several spike proteins and N protein) and human antibodies and nanobodies , contributing to the evaluation and development of therapeutics and diagnostics.

One or more keywords matched the following items that are connected to Cavacini, Lisa
Item TypeName
Concept Immunization, Passive
Academic Article Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques.
Academic Article Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques.
Academic Article Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
Academic Article Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
Academic Article Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.
Academic Article Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission?
Academic Article Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies.
Academic Article T-cell immunity in murine malaria: adoptive transfer of resistance to Plasmodium chabaudi adami in nude mice with splenic T cells.
Academic Article Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.
Academic Article Preformulation Characterization and Stability Assessments of Secretory IgA Monoclonal Antibodies as Potential Candidates for Passive Immunization by Oral Administration.
Academic Article Formulation Studies to Develop Low-Cost, Orally-Delivered Secretory IgA Monoclonal Antibodies for Passive Immunization Against Enterotoxigenic Escherichia coli.
Search Criteria
  • Immunotherapy Passive